anastrozole has been researched along with Bone Fractures in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 9.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "27, postmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 mg, daily." | 9.19 | Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014) |
| "Incidence of joint symptoms and bone fractures as well as changes in bone mineral density (BMD) in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole were investigated to determine whether there is an ethnic difference from Caucasian patients in the incidence of these adverse events of anastrozole." | 9.14 | Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. ( Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y, 2009) |
| "The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer." | 9.13 | Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. ( Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R, 2008) |
| "These data show long-term safety findings and establish clearly the long-term efficacy of anastrozole compared with tamoxifen as initial adjuvant treatment for postmenopausal women with hormone-sensitive, early breast cancer, and provide statistically significant evidence of a larger carryover effect after 5 years of adjuvant treatment with anastrozole compared with tamoxifen." | 9.13 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS, 2008) |
| "Because of its superior efficacy to tamoxifen, anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients." | 7.80 | A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). ( Futsuhara, K; Kai, T; Kojima, M; Tabei, T; Takei, H; Takeuchi, H; Yoshida, T, 2014) |
| "Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported." | 7.76 | Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| "Anastrozole induced an increase in bone remodelling: osteocalcin (+36." | 6.73 | Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. ( Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F, 2007) |
| "In this prospective, phase 3 trial, we randomly assigned postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy to receive the aromatase inhibitor anastrozole for an additional 2 years (2-year group, receiving a total of 7 years) or an additional 5 years (5-year group, receiving a total of 10 years)." | 5.41 | Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. ( Balic, M; Bartsch, R; Bjelic-Radisic, V; Brunner, C; Deutschmann, C; Egle, D; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Greil-Ressler, S; Haslbauer, F; Heck, D; Jakesz, R; Kacerovsky-Strobl, S; Manfreda, D; Melbinger-Zeinitzer, E; Rinnerthaler, G; Sevelda, P; Singer, CF; Soelkner, L; Steger, GG; Suppan, C; Thaler, J; Trapl, H; Wette, V; Wieder, U; Wimmer, K, 2021) |
| " 3 year) in postmenopausal women with breast cancer previously treated with 2-3 years of tamoxifen." | 5.30 | Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG, 2019) |
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 5.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "27, postmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 mg, daily." | 5.19 | Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014) |
| "Incidence of joint symptoms and bone fractures as well as changes in bone mineral density (BMD) in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole were investigated to determine whether there is an ethnic difference from Caucasian patients in the incidence of these adverse events of anastrozole." | 5.14 | Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. ( Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y, 2009) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| "The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer." | 5.13 | Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. ( Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R, 2008) |
| "These data show long-term safety findings and establish clearly the long-term efficacy of anastrozole compared with tamoxifen as initial adjuvant treatment for postmenopausal women with hormone-sensitive, early breast cancer, and provide statistically significant evidence of a larger carryover effect after 5 years of adjuvant treatment with anastrozole compared with tamoxifen." | 5.13 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS, 2008) |
| "This prospectively designed subprotocol (n = 308) of ATAC assessed changes in BMD and bone turnover markers in postmenopausal women with invasive primary breast cancer receiving anastrozole 1 mg/day, tamoxifen 20 mg/day, or combination treatment with both agents for 5 years." | 5.12 | Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). ( Adams, JE; Clack, G; Cuzick, J; Dowsett, M; Eastell, R; Hannon, RA, 2006) |
| "Because of its superior efficacy to tamoxifen, anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients." | 3.80 | A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). ( Futsuhara, K; Kai, T; Kojima, M; Tabei, T; Takei, H; Takeuchi, H; Yoshida, T, 2014) |
| "Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported." | 3.76 | Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| ", versus a control group of healthy postmenopausal women): (a) healthy postmenopausal women receiving tamoxifen; (b) postmenopausal women who had received treatment for early breast cancer; (c) postmenopausal breast cancer patients on adjuvant tamoxifen therapy; (d) postmenopausal breast cancer patients on adjuvant anastrozole therapy." | 3.74 | Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer. ( Bell, R; Lewis, J, 2007) |
| "Anastrozole induced an increase in bone remodelling: osteocalcin (+36." | 2.73 | Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. ( Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F, 2007) |
| "Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels." | 2.44 | Skeletal effects of drugs to treat cancer. ( Vestergaard, P, 2008) |
| "Bone loss may be a potential side effect of implementing aromatase inhibitors in the adjuvant setting." | 2.43 | Bone safety of aromatase inhibitors versus tamoxifen. ( Lønning, PE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Gnant, M | 1 |
| Fitzal, F | 1 |
| Rinnerthaler, G | 1 |
| Steger, GG | 1 |
| Greil-Ressler, S | 1 |
| Balic, M | 1 |
| Heck, D | 1 |
| Jakesz, R | 1 |
| Thaler, J | 1 |
| Egle, D | 1 |
| Manfreda, D | 1 |
| Bjelic-Radisic, V | 1 |
| Wieder, U | 1 |
| Singer, CF | 1 |
| Melbinger-Zeinitzer, E | 1 |
| Haslbauer, F | 1 |
| Sevelda, P | 1 |
| Trapl, H | 1 |
| Wette, V | 1 |
| Wimmer, K | 1 |
| Gampenrieder, SP | 1 |
| Bartsch, R | 1 |
| Kacerovsky-Strobl, S | 1 |
| Suppan, C | 1 |
| Brunner, C | 1 |
| Deutschmann, C | 1 |
| Soelkner, L | 1 |
| Fesl, C | 1 |
| Greil, R | 1 |
| van Hellemond, IEG | 1 |
| Smorenburg, CH | 1 |
| Peer, PGM | 1 |
| Swinkels, ACP | 1 |
| Seynaeve, CM | 1 |
| van der Sangen, MJC | 1 |
| Kroep, JR | 1 |
| de Graaf, H | 1 |
| Honkoop, AH | 1 |
| Erdkamp, FLG | 1 |
| van den Berkmortel, FWPJ | 1 |
| de Boer, M | 1 |
| de Roos, WK | 1 |
| Linn, SC | 1 |
| Imholz, ALT | 1 |
| Tjan-Heijnen, VCG | 1 |
| Sestak, I | 1 |
| Blake, GM | 1 |
| Patel, R | 1 |
| Coleman, RE | 2 |
| Cuzick, J | 3 |
| Eastell, R | 3 |
| Boccardo, F | 1 |
| Guglielmini, P | 1 |
| Bordonaro, R | 1 |
| Fini, A | 1 |
| Massidda, B | 1 |
| Porpiglia, M | 1 |
| Roagna, R | 1 |
| Serra, P | 1 |
| Orzalesi, L | 1 |
| Ucci, G | 1 |
| Rubagotti, A | 1 |
| Goss, PE | 2 |
| Hershman, DL | 1 |
| Cheung, AM | 1 |
| Ingle, JN | 1 |
| Khosla, S | 1 |
| Stearns, V | 1 |
| Chalchal, H | 1 |
| Rowland, K | 1 |
| Muss, HB | 1 |
| Linden, HM | 1 |
| Scher, J | 1 |
| Pritchard, KI | 1 |
| Elliott, CR | 1 |
| Badovinac-Crnjevic, T | 1 |
| St Louis, J | 1 |
| Chapman, JA | 1 |
| Shepherd, LE | 1 |
| Vestergaard, P | 1 |
| Lester, JE | 1 |
| Dodwell, D | 1 |
| Purohit, OP | 1 |
| Gutcher, SA | 1 |
| Ellis, SP | 1 |
| Thorpe, R | 1 |
| Horsman, JM | 1 |
| Brown, JE | 1 |
| Hannon, RA | 3 |
| Okishiro, M | 1 |
| Taguchi, T | 1 |
| Kim, SJ | 1 |
| Tanji, Y | 1 |
| Shimazu, K | 1 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Sagara, Y | 3 |
| Kosha, S | 1 |
| Baba, S | 1 |
| Dokiya, F | 1 |
| Tamada, S | 1 |
| Matsuyama, Y | 1 |
| Ohi, Y | 1 |
| Ando, M | 1 |
| Rai, Y | 1 |
| Douchi, T | 1 |
| Van Poznak, C | 1 |
| Mackey, JR | 1 |
| Campone, M | 1 |
| Apffelstaedt, JP | 1 |
| Clack, G | 2 |
| Barlow, D | 1 |
| Makris, A | 1 |
| Takeuchi, H | 1 |
| Takei, H | 1 |
| Futsuhara, K | 1 |
| Yoshida, T | 1 |
| Kojima, M | 1 |
| Kai, T | 1 |
| Tabei, T | 1 |
| Aumiller, J | 1 |
| Denes, AE | 1 |
| Dowsett, M | 1 |
| Adams, JE | 1 |
| Lønning, PE | 1 |
| Chien, AJ | 1 |
| Bell, R | 1 |
| Lewis, J | 1 |
| Gralow, JR | 1 |
| Confavreux, CB | 1 |
| Fontana, A | 1 |
| Guastalla, JP | 1 |
| Munoz, F | 1 |
| Brun, J | 1 |
| Delmas, PD | 1 |
| Forbes, JF | 1 |
| Buzdar, A | 1 |
| Howell, A | 1 |
| Tobias, JS | 1 |
| Baum, M | 1 |
| Toi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy[NCT00295620] | Phase 3 | 3,484 participants (Actual) | Interventional | 2004-03-01 | Completed | ||
| A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.[NCT00301457] | Phase 3 | 1,914 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer[NCT00354302] | Phase 3 | 497 participants (Actual) | Interventional | 2006-04-24 | Completed | ||
| Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.[NCT03784651] | 120 participants (Anticipated) | Observational | 2018-12-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival. (NCT00295620)
Timeframe: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of overall survival. (NCT00295620)
Timeframe: Overall survival was defined as the time from two years after randomization to death due to any cause, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of lowering the risk of contralateral breast cancer. Subjects without contralateral breast cancer event were censored at the last date when they were known to be contralateral breast cancer free. (NCT00295620)
Timeframe: Risk of contralateral breast cancer was defined as the time from two years after randomization to first occurrence of new contralateral breast cancer, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine the effect of 2 years versus 5 years of additional Anastrozole after 5 years of adjuvant endocrine therapy on the time to first clinical fracture. Patients without clinical fractures where censored at their last therapy visit (approximately 5 years after randomization). (NCT00295620)
Timeframe: Time to first clinical fracture was defined as time to first clinical fracture, in the period from 2 years until 5 years after randomization for each patient.
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of lowering the risk of secondary carcinoma. Subjects without secondary cancer event were censored at the last date when they were known to be secondary cancer free. (NCT00295620)
Timeframe: Risk of secondary carcinoma was defined as the time from two years after randomization to first occurrence of new secondary cancer without new breast cancer (local or contralateral), assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
3 reviews available for anastrozole and Bone Fractures
| Article | Year |
|---|---|
Skeletal effects of drugs to treat cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Diseases, Meta | 2008 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ar | 2006 |
11 trials available for anastrozole and Bone Fractures
| Article | Year |
|---|---|
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brea | 2021 |
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bon | 2019 |
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2008 |
Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Chemotherapy, | 2009 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Co | 2007 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free | 2008 |
7 other studies available for anastrozole and Bone Fractures
| Article | Year |
|---|---|
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Breast | 2010 |
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clini | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemothera | 2005 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuv | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromata | 2007 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |